Novonesis (Novozymes) B (FRA:NZM) Other Stockholders Equity: €-297 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NZM Novonesis (Novozymes) B FRA:NZM
93 GF Score
Price €56.00
GF Value €56.81
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Novonesis (Novozymes) B Other Stockholders Equity?

Novonesis (Novozymes) B FRA:NZM 93 Other Stockholders Equity is €-297 Mil as of Mar. 2026. GuruFocus rates FRA:NZM with a GF Score™ of 93/100 and a GF Value™ of €56.81 (Fairly Valued). The stock has 4 warning signs investors should review.

Novonesis (Novozymes) B's Other Stockholders Equity for the quarter that ended in Mar. 2026 was €-297 Mil.

Novonesis (Novozymes) B's quarterly Other Stockholders Equity declined from Sep. 2025 (€-420 Mil) to Dec. 2025 (€-429 Mil) but then increased from Dec. 2025 (€-429 Mil) to Mar. 2026 (€-297 Mil).

Novonesis (Novozymes) B's annual Other Stockholders Equity increased from Dec. 2023 (€-45 Mil) to Dec. 2024 (€18 Mil) but then declined from Dec. 2024 (€18 Mil) to Dec. 2025 (€-429 Mil).

Novonesis (Novozymes) B Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Novonesis (Novozymes) B's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novonesis (Novozymes) B Other Stockholders Equity Chart

Novonesis (Novozymes) B Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.38 28.59 -45.40 18.00 -428.80

Novonesis (Novozymes) B Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -99.20 -419.40 -420.10 -428.80 -297.10
FRA:NZM
93GF Score
Novonesis (Novozymes) B FRA:NZM
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novonesis (Novozymes) B Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €-297 Mil mean?
Novonesis (Novozymes) B (FRA:NZM) has a Other Stockholders Equity of €-297 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Novonesis (Novozymes) B and its competitors.
Is Novonesis (Novozymes) B's Other Stockholders Equity too high?
Novonesis (Novozymes) B's current Other Stockholders Equity is €-297 Mil. Overall, Novonesis (Novozymes) B has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's Other Stockholders Equity compare to LIN and SHW?
Novonesis (Novozymes) B's Other Stockholders Equity of €-297 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Chemicals company?
A good Other Stockholders Equity depends on the Chemicals industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Novonesis (Novozymes) B and its competitors. Novonesis (Novozymes) B's current Other Stockholders Equity is €-297 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Based on GuruFocus' analysis, Novonesis (Novozymes) B (FRA:NZM) is currently considered Fairly Valued. The stock's GF Value™ is €56.81, compared to a current price of €56.00 — trading 1.4% below its estimated fair value. The current Other Stockholders Equity is €-297 Mil. Novonesis (Novozymes) B's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Novonesis (Novozymes) B (FRA:NZM), the current Other Stockholders Equity is €-297 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novonesis (Novozymes) B (FRA:NZM) Overvalued in 2026?

Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be undervalued. The current stock price of €56.00 is trading 1.4% below its estimated GF Value™ of €56.81. GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.

Key valuation signals for FRA:NZM:

  • Other Stockholders Equity: €-297 Mil
  • GF Value™: €56.81 vs. price of €56.00 (1.4% below fair value)
  • GF Score™: 93/100 with 4 warning signs

No single metric tells the full story. See the FRA:NZM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novonesis (Novozymes) B Business Description

Address Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
93GF Score

Get the complete analysis for FRA:NZM

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€56.00
Price
€56.81
GF Value